Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Lost Generation: Weak Progeny From Pfizer And Wyeth R&D

This article was originally published in The Pink Sheet Daily

Executive Summary

An update on the drugs that were supposed to be the stars of a new generation of Pfizer and Wyeth products.

You may also be interested in...

Pfizer & Wyeth: Is Mega Merger A Strategic Move Or Desperate Play?

Combination of Pfizer and Wyeth would create a drug powerhouse with combined sales of over $70 billion, strengthen Pfizer’s position in biotech and vaccines and create billions in cost savings opportunities.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts